This content is machine translated Therapy with Small Molecules JAK inhibitors in inflammatory dermatoses on the rise In inflammatory processes of dermatological diseases, pro-inflammatory cytokines play a central role. Therefore they are in focus therapeutic approaches when it comes to breaking critical signaling pathways. In addition to monoclonal…
View Post 4 min This content is machine translated Atopic dermatitis Long-term efficacy of baricitinib proven In adult patients with moderate to severe atopic dermatitis, long-term therapy with the JAK inhibitor baricitinib maintained improvements achieved after 16 weeks for 68 weeks, new data show. A pooled…
View Post 5 min This content is machine translated Moderate to severe atopic dermatitis Biologic therapy in the changing times: “Best practice” approaches in focus In addition to the new systemic drugs recently launched, several active substances are currently in development. These include some biologics in advanced stages of clinical testing. Overall, the future prospects…
View Post 4 min This content is machine translated Atopic dermatitis JAK inhibition as a mode of action – an update. Janus kinase (JAK) inhibitors are a promising new treatment option for adult patients with atopic eczema, given their rapid relief of pruritus and inflammatory lesions. In addition to baricitinib, which…
View Post 3 min This content is machine translated Baricitinib First oral JAK inhibitor approved for the treatment of atopic dermatitis The use of small molecule drugs for the treatment of atopic dermatitis has been investigated for some time. With the approval of the Janus kinase (JAK) inhibitor baricitinib, a new…
View Post 5 min This content is machine translated Myelofibrosis Treatment in transition With the introduction of the Janus kinase (JAK) inhibitor ruxolitinib, therapy for myelofibrosis has changed dramatically in recent years. Nevertheless, further innovation is needed, especially in the second line. Promising…
